
Congresos
Materiales de congresos
Tenga acceso a resúmenes, pósteres y presentaciones de los siguientes congresos
Septiembre 2023
Sociedad Española de Oncología Médica (SEOM)
Sociedad Española de Oncología Médica (SEOM)
Septiembre 2023 (Barcelona, España)
Septiembre 2023
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
September 2023 (Katowice, Poland)
Presentaciones
Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Pósteres
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Resúmenes
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib demonstrated superior progression-free survival vs ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: final analysis of phase 3 ALPINE study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Septiembre 2023
World Conference on Lung Cancer (WCLC)
World Conference on Lung Cancer (WCLC)
September 2023 (Singapore)
Presentaciones
Septiembre 2023
KSMO (Sociedad Coreana de Oncología Médica)
KSMO (Sociedad Coreana de Oncología Médica)
September 2023 (Seoul, Korea)
Pósteres
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a phase Ib/II study
RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy versus placebo + chemotherapy as first first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma
Resúmenes
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: updated results from a phase Ib/II study
RATIONALE-305: Phase 3 study of tislelizumab plus chemotherapy versus placebo + chemotherapy as first first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma
Agosto 2023
Asia-Pacific Gastroenterology Cancer Summit (APGCS)
Asia-Pacific Gastroenterology Cancer Summit (APGCS)
August 2023 (Singapore)
Pósteres
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Resúmenes
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Agosto 2023
International Society for Pharmacoepidemiology (ICPE)
International Society for Pharmacoepidemiology (ICPE)
August 2023 (Halifax, Nova Scotia, Canada)
Agosto 2023
American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)
American Society of Clinical Oncology - Breakthrough (ASCO Breakthrough)
August 2023 (Yokohama, Japan)
Presentaciones
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Julio 2023
Translational Summit on Hematologic Malignancies (DAVA Oncology Meetings)
Translational Summit on Hematologic Malignancies (DAVA Oncology Meetings)
July 2023 (Bermuda)
Pósteres
Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors
Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Junio 2023
WCGI (World Congress on Gastrointestinal Cancer)
WCGI (World Congress on Gastrointestinal Cancer)
Junio 2023 (Barcelona, España)
Junio 2023
Health Technology Assessment international (HTAi)
Health Technology Assessment international (HTAi)
Junio de 2023 (Adelaida, Australia Meridional, Australia)
Junio 2023
European Association for the Study of the Liver (EASL)
European Association for the Study of the Liver (EASL)
Junio 2023 (Viena, Austria)
Pósteres
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the Rationale-301 study
Impact of baseline liver function on overall survival and safety in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab: results from the rationale-301 study
Resúmenes
Association of tumor response with survival in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab versus sorafenib: results from the Rationale-301 study
Impact of baseline liver function on overall survival and safety in patients with unresectable hepatocellular carcinoma treated with first-line tislelizumab: results from the rationale-301 study
Junio 2023
ICML (International Conference on Malignant Lymphoma)
ICML (International Conference on Malignant Lymphoma)
Junio 2023 (Lugano, Suiza)
Presentaciones
Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: extended follow-up of the SEQUOIA study
Pósteres
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
First interim analysis of a phase 1 study of zanubrutinib + lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Long-term efficacy and safety of zanubrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Matching-adjusted indirect comparison (MAIC) of zanubrutinib vs ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL)
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: post hoc analysis of a large clinical trial safety database
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life
Resúmenes
A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia (CLL)
A phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib: preliminary results for patients with CLL/SLL
First interim analysis of a phase 1 study of zanubrutinib (zanu) + lenalidomide (len) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Long-term efficacy and safety of zanubrutinib (ZANU) in relapsed/refractory marginal zone lymphoma (R/R MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Long-term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma
Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) vs ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) CLL/SLL: extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab vs obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B-cell malignancies: Post hoc analysis of a large clinical trial safety database
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life
Junio 2023
EHA (Asociación Europea de Hematología)
EHA (Asociación Europea de Hematología)
Junio de 2023 (Fráncfort, Alemania)
Pósteres
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models
Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors
Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Comparative efficacy of zanubrutinib versus rituximab in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Health-relayed quality of life in patients with Waldenström macroglobulinemia (WM) treated with zanubrutinib vs ibrutinib: results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Matching-adjusted indirect comparison (MAIC) of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma (R/R MZL)
Real-world treatment patterns of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma in community oncology practices in the United States
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Resúmenes
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
BGB-16673, a BTK degrader, overcomes on-target resistance from BTK inhibitors and presents sustainable long-term tumor regression in lymphoma xenograft models
Bruton tyrosine kinase (BTK) protein degrader BGB-16673 is less apt to cause, and able to overcome variable BTK resistance mutations compared to other BTK inhibitors (BTKi)
Characterization of zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database
Comparative efficacy of zanubrutinib (zanu) versus rituximab (rtx) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
Efficacy and safety of once daily (QD) vs twice daily (BID) zanubrutinib for patients with various B-cell malignancies: a comparative summary of clinical data and exposure-response analysis
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Health-related quality of life in patients (pts) with Waldenström macroglobulinemia (WM) treated with zanubrutinib (zanu) vs ibrutinib (ibr): results from the phase 3 ASPEN trial long-term follow-up
Long-term efficacy and safety of zanubrutinib (zanu) in patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Matching-adjusted indirect comparison (MAIC) of zanubrutinib (zanu) versus ibrutinib (ibru) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Persistence with oral therapy as reflection of actual compliance for chronic lymphocytic leukemia (CLL) - a national prescribed drug and patient registered study from Sweden
Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US)
The meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia
Updated safety and efficacy results of zanubrutinib in patients with B-cell malignancies who are intolerant of ibrutinib and/or acalabrutinib
Zanubrutinib (zanu) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): extended follow-up of the SEQUOIA study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Zanubrutinib vs ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): impact on health-related quality of life (HRQoL)
Junio 2023
ASCO (Sociedad Estadounidense de Oncología Clínica)
ASCO (Sociedad Estadounidense de Oncología Clínica)
Junio de 2023 (Chicago, Illinois, EE. UU.)
Presentaciones
Pósteres
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
First interim analysis of a phase 1 study of zanubrutinib plus lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a phase Ib/II study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed or refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Resúmenes
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies
A phase 1 study of the OX40 agonist, BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC)
Comparative efficacy of zanubrutinib (ZANU) versus rituximab (RTX) in relapsed marginal zone lymphoma (MZL): matching-adjusted indirect comparison (MAIC)
First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS)
MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma
Matching-adjusted indirect comparison (MAIC) of zanubrutinib (ZANU) versus ibrutinib (IBRU) in relapsed/refractory marginal zone lymphoma (R/R MZL)
Real-world treatment patterns of Bruton tyrosine kinase inhibitors (BTKi) in patients with mantle cell lymphoma (MCL) in community oncology practices in the United States (US)
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: zanidatamab in previously- treated HER2-amplified biliary tract cancer (BTC)
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 European/North American (EU/NA) subgroup
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): updated results from a Phase Ib/II study
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study
Mayo 2023
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
Mayo de 2023 (Boston, MA, Estados Unidos)
Abril 2023
BSH (Sociedad Británica de Hematología)
BSH (Sociedad Británica de Hematología)
Abril de 2023 (Birmingham, Inglaterra)
Presentaciones
Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)
Pósteres
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Resúmenes
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination therapy with zanubrutinib in non-Hodgkin lymphoma or Waldenström macroglobulinemia patients
BGB-11417 (Bcl-2 inhibitor) monotherapy or combination with zanubrutinib in CLL/SLL patients: preliminary phase 1 data
Preliminary safety and efficacy of BGB-11417 (novel Bcl-2 inhibitor) in combination with azacitidine in AML
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 Study
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib demonstrates superior progression-free survival vs ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214)
Abril 2023
AACR (Asociación Estadounidense de Investigación en Cáncer)
AACR (Asociación Estadounidense de Investigación en Cáncer)
Abril de 2023 (Orlando, Florida, EE. UU.)
Presentaciones
A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors
Pósteres
Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302.
BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel
Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Resúmenes
A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
Association of tumor mutational burden (TMB) and clinical outcomes with tislelizumab versus chemotherapy in esophageal squamous cell carcinoma (ESCC) from RATIONALE-302.
BGB-24714, a novel oral IAP antagonist, displayed significant anti-tumor activities in preclinical models as a monotherapy and in combination with paclitaxel
Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
Safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors
Marzo 2023
SFH (Sociedad Francesa de Hematología)
SFH (Sociedad Francesa de Hematología)
Marzo 2023 (París, Francia)
Presentaciones
Pósteres
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Resúmenes
A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
A phase 1 study with the novel B-cell lymphoma (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin's lymphoma or Waldenström macroglobulinemia
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free survival versus ibrutinib for relapsed/refractory CLL/SLL: ALPINE final analysis
Marzo 2023
Hematology/Oncology Pharmacy Association (HOPA)
Hematology/Oncology Pharmacy Association (HOPA)
Marzo de 2023 (Phoenix, Arizona, EE. UU.)
Pósteres
Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Zanubrutinib demonstrates superior progression-free survival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Marzo 2023
Cumbre de Whistler sobre neoplasias hematológicas (reuniones de oncología de DAVA)
Cumbre de Whistler sobre neoplasias hematológicas (reuniones de oncología de DAVA)
Marzo de 2023 (Whistler, Columbia Británica, Canadá)
Pósteres
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Rate of atrial fibrillation in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib demonstrates superior progression-free survival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Marzo 2023
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
American Society for Clinical Pharmacology & Therapeutics (ASCPT)
Marzo de 2023 (Atlanta, Georgia, EE. UU.)
Marzo 2023
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
Marzo 2023 (París, Francia)
Marzo 2023
JSMO (Sociedad Japonesa de Oncología Médica)
JSMO (Sociedad Japonesa de Oncología Médica)
Marzo de 2023 (Fukuoka, Japón)
Febrero 2023
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM)
International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma (ICHM)
Febrero de 2023 (Miami Beach, Florida, EE. UU.)
Pósteres
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients with B-cell malignancies who undergo treatment with zanubrutinib
Zanubrutinib in patients with B-cell malignancies intolerant to acalabrutinib
Resúmenes
Preliminary safety of Bcl-2 inhibitor BGB-11417 in relapsed/refractory multiple myeloma harboring t(11,14): phase 1b/2 study
Rate of cardiac disorders in patients (pts) with B-cell malignancies who undergo treatment with zanubrutinib (zanu)
Zanubrutinib (zanu) in patients (pts) with B-cell malignancies intolerant to acalabrutinib (acala)
Febrero 2023
ASCO-GU (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Genitourinarios)
ASCO-GU (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Genitourinarios)
Febrero de 2023 (San Francisco, California, EE. UU.)
Febrero 2023
Reuniones sobre trasplante y terapia celular de ASTCT y CIBMTR (Tandem)
Reuniones sobre trasplante y terapia celular de ASTCT y CIBMTR (Tandem)
Febrero de 2023 (Orlando, Florida, EE. UU.)
Enero 2023
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
Enero de 2023 (San Francisco, California, EE. UU.)
Presentaciones
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Pósteres
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Resúmenes
RATIONALE 305: phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): non-Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 population
Diciembre 2022
ASH (Sociedad Estadounidense de Hematología)
ASH (Sociedad Estadounidense de Hematología)
Diciembre de 2022 (Nueva Orleans, Luisiana, EE. UU.)
Presentaciones
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with CLL/SLL: preliminary data
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Zanubrutinib demonstrates superior progression-free surivival compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from final analysis of ALPINE randomized phase 3 study
Pósteres
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with non-Hodgkin lymphoma or Waldenström macroglobulinemia: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relaped/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a nonrandomized, open-label, phase 1b/2 study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Resúmenes
A phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies: preliminary data
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with non-Hodgkin lymphoma or Waldenström macroglobulinemia (WM): preliminary data
A phase 1 with the novel B-cell lymphoma 2 (Bcl-1) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with CLL/SLL: preliminary data
Biomarker analysis of zanubrutinib and tislelizumab combination therapy in patients with relapsed/refractory B-cell malignancies
Development of hypertension and atrial fibrillation following diagnosis of B-cell malignancies - a retrospective analysis of US MarketScan insurance claims database
Efficacy and safety of zanubrutinib in Japanese patients with mature B-cell malignancies
Genomic characterization of patients in a phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients with relapsed/refractory B-cell malignancies
Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the MAGNOLIA (BGB-3111-214) trial
Long-term outcomes of second-line vs later-line zanubrutinib treatment in patients with relapsed/refractory MCL: an updated pooled analysis
Preliminary safety and efficacy of BGB-11417, a novel Bcl-2 inhibitor, in combination with azacitidine in patients with acute myeloid leukemia (AML)
Preliminary safety and efficacy of zanubrutinib in combination with lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma
Preliminary safety of a Bcl-2 inhibitor, BGB-11417, in patients with relapsed/refractory multiple myeloma harboring t(11,14): a non-randomized, open-label, phase 1b/2 study
Real-world evidence (RWE) studies supported hematologic oncology United States Food and Drug Administration (US FDA) approval: what do they look like?
Zanubrutinib demonstrates superior progression-free survival (PFS) compared with ibrutinib for treatment of relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL): results from final analysis of ALPINE randomized phase 3 study
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Diciembre 2022
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
ESMO-IO (Inmunooncología de la Sociedad Europea de Oncología Médica)
Diciembre 2022 (Ginebra, Suiza)
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced NSCLC
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer: RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer: RATIONALE-307 updated analysis
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with checkpoint inhibitor-experienced advanced non-small cell lung cancer
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with extensive-stage small cell lung cancer
Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: A single-arm, multicenter, phase II trial
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer : RATIONALE-304 updated analysis
Randomized phase 3 study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer : RATIONALE-307 updated analysis
Diciembre 2022
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
ESMO-Asia (Sociedad Europea de Oncología Médica - Asia)
Diciembre de 2022 (Singapur)
Presentaciones
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab plus chemotherapy vs chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): Asia subgroup
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: the RATIONALE-301 Chinese subpopulation analysis
Resúmenes
Patterns of treatment and outcomes in CLL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
Patterns of treatment and outcomes in MCL patients in Australia: an analysis of the population-wide pharmaceutical benefits scheme dataset
RATIONALE-302: tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): impact on health-related quality of life (HRQoL) in Asian patients
RATIONALE-309: effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Randomized, global, phase 3 study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Tislelizumab (TIS) versus sorafenib (SOR) in first-line (1L) treatment of unresectable hepatocellular carcinoma (HCC): the RATIONALE-301 Chinese subpopulation analysis
Noviembre 2022
DKK (Congreso oncológico de Alemania)
DKK (Congreso oncológico de Alemania)
Noviembre 2022 (Berlín, Alemania)
Noviembre 2022
KALC (Asociación Coreana de Cáncer de Pulmón)
KALC (Asociación Coreana de Cáncer de Pulmón)
Noviembre 2022 (Seúl, Corea del Sur)
Presentaciones
Noviembre 2022
SITC (Sociedad de Inmunoterapia contra el Cáncer)
SITC (Sociedad de Inmunoterapia contra el Cáncer)
Noviembre de 2022 (Boston, Massachusetts, EE. UU.)
Pósteres
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Resúmenes
DKN-01 and tislelizumab as a second-line investigational therapy in advanced DKK1-high gastroesophageal adenocarcinoma : DisTinGuish trial
Peripheral pharmacodynamic effects of ociperlimab in combination with tislelizumab in patients with advanced solid tumors: AdvanTIG-105 Phase 1 dose-escalation study
Noviembre 2022
SPH (Sociedad Portuguesa de Hematología)
SPH (Sociedad Portuguesa de Hematología)
Noviembre 2022 (Tróia, Portugal)
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (Bcl-2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
Long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Noviembre 2022
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
ISPOR-EU (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados - Europa)
Noviembre 2022 (Viena, Austria)
Pósteres
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact analysis of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Resúmenes
Budget impact analysis of zanubrutinib for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma in the United States
Budget impact of zanubrutinib for treatment of relapsed or refractory chronic lymphocytic leukemia in the United States
Lessons learned from successful real-world evidence (RWE) studies supporting regulatory drug approvals
Zanubrutinib versus ibrutinib to treat adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a cost per responder model from a payer perspective in the United States
Noviembre 2022
CSCO (Sociedad China de Oncología Clínica)
CSCO (Sociedad China de Oncología Clínica)
Noviembre 2022 (China)
Presentaciones
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
Pósteres
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for nonsquamous nsclc in patients aged 65-75 years
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (her2+) advanced/metastatic gastroesophageal adenocarcinoma
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Resúmenes
Time to response and depth of response in non-squamous non-small cell lung cancer patients treated with tislelizumab plus chemotherapy as first line therapy: an exploratory analysis of RATIONALE-304
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with locally advanced non-small cell lung cancer: asian versus non-asian subgroup analysis of the RATIONALE-303 study
RATIONALE-304: tislelizumab plus chemotherapy versus chemotherapy alone as first line treatment for nonsquamous non-small cell lung cancer in patients aged 65-75 years
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
A matching-adjusted indirect comparison of tislelizumab versus camrelizumab as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-105: a phase 1 dose-verification study of ociperlimab in combination with tislelizumab in advanced solid tumors in Chinese patients
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvantTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic non-small cell lung cancer
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive advanced or metastatic gastroesophageal adenocarcinoma
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Rationale-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced nonsquamous non-small cell lung cancer
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer
The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen
Tislelizumab versus docetaxel in patients with previously treated advanced nonsquamous non-small cell lung cancer: subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous non-small cell lung cancer: sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Zanubrutinib plus obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Noviembre 2022
COSA (Sociedad Australiana de Oncología Clínica)
COSA (Sociedad Australiana de Oncología Clínica)
Noviembre 2022 (Brisbane, Australia)
Pósteres
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Resúmenes
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer
Octubre 2022
IWWM (Taller internacional sobre la macroglobulinemia de Waldenström)
IWWM (Taller internacional sobre la macroglobulinemia de Waldenström)
Octubre 2022 (Madrid, España)
Presentaciones
ASPEN biomarker analysis: response to BTK inhibitor treatment in patients with Waldenström macroglobulinemia harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Extended follow-up of a phase 2 trial of the Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Zanubrutinib in patients intolerant to ibrutinib/acalabrutinib
Zanubrutinib or the treatment of patients with Waldenström macroglobulinemia: 4 years of follow-up
Resúmenes
ASPEN biomarker analysis: response to Bruton Tyrosine Kinase Inhibitor (BTKi) treatment in patients with Waldenström macroglobulinemia (WM) harboring CXCR4, TP53, and TERT mutations
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
Extended follow-up of a phase 2 trial of the Bruton tyrosine-kinase inhibitor zanubrutinib (BGB-3111) in Chinese patients with relapsed/refractory Waldenström macroglobulinemia
Preliminary results for patients with Waldenström macroglobulinemia from the phase 2 study of zanubrutinib in previously treated B-cell malignancies intolerant to ibrutinib and/or acalabrutinib
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Octubre 2022
JSCO (Sociedad Japonesa de Oncología Clínica)
JSCO (Sociedad Japonesa de Oncología Clínica)
Octubre 2022 (Kobe, Japón)
Octubre 2022
Linfoma, leucemia y mieloma (LLM)
Linfoma, leucemia y mieloma (LLM)
Octubre de 2022 (Nueva York, Nueva York, EE. UU.)
Octubre 2022
JSH (Sociedad Japonesa de Hematología)
JSH (Sociedad Japonesa de Hematología)
Octubre 2022 (Fukuoka, Japón)
Octubre 2022
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
DGHO (Sociedades Alemana, Austríaca y Suiza de Hematología y Oncología Médica)
Octubre 2022 (Viena, Austria)
Presentaciones
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Pósteres
Randomized, phase 3 study of second-line treatment vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
RATIONALE 302: randomized, phase 3 study of tislelizumab vs chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302) in the overall population and Europe/North America subgroup
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQOL)
Octubre 2022
SEHH (Sociedad Española de Hematología y Hemoterapia)
SEHH (Sociedad Española de Hematología y Hemoterapia)
Octubre 2022 (Barcelona, España)
Presentaciones
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (Bcl-2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve CLL/SLL
Pósteres
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
SOHO (Sociedad de Oncología Hematológica)
SOHO (Sociedad de Oncología Hematológica)
Septiembre de 2022 (Houston, Texas, EE. UU.)
Pósteres
A phase 1 study with the novel Bcl-2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs. ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine and rituximab (BR) in patients with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
SIE (Sociedad Italiana de Hematología)
SIE (Sociedad Italiana de Hematología)
Septiembre 2022 (Roma, Italia)
Presentaciones
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma: subgroup analysis of the MAGNOLIA study
Zanubrutinib plus obtinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Pósteres
A phase 2 study with the novel B-cell lymphoma (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Resúmenes
A phase 2 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients (pts) with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib (zanu) in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Septiembre 2022
NZSO (Sociedad de Oncología de Nueva Zelanda)
NZSO (Sociedad de Oncología de Nueva Zelanda)
Septiembre 2022 (Christchurch, Nueva Zelanda)
Septiembre 2022
HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)
HSANZ (Sociedad de Hematología de Australia y Nueva Zelanda)
Septiembre 2022 (Sídney, Australia)
Presentaciones
A phase 1 study with the novel BCL2 inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory CLL/SLL
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with AML
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Pósteres
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia
Population-wide patterns of care in CLL in Australia: an analysis of the pharmaceutical benefits scheme data set
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme data set
Resúmenes
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib vs ibrutinib in patients with Waldenström macroglobulinemia (WM)
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Population-wide patterns of care in chronic lymphocytic leukemia (CLL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Population-wide patterns of care in mantle cell lymphoma (MCL) in Australia: an analysis of the pharmaceutical benefits scheme (PBS) dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia (AML)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
ESMO (Sociedad Europea de Oncología Médica)
ESMO (Sociedad Europea de Oncología Médica)
Septiembre 2022 (París, Francia)
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab + tislelizumab with chemotherapy in patients with metastatic squamous and nonsquamous non-small cell lung cancer
AdvanTIG-205: phase 2 trial of ociperlimab plus tislelizumab plus chemotherapy in first-line treatment of patients with locally advanced, unresectable, or metastatic non-small cell lung cancer
DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
SAFFRON-301: a phase 3 study of tislelizumab with sitravatinib versus chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer previously treated with platinum-based chemotherapy and an anti-PD-1/PD-L1 antibody
Tislelizumab versus docetaxel as second- or third-line therapy in previously treated patients with advanced non-small cell lung cancer (NSCLC): Asian and non-Asian subgroup analysis of the RATIONALE-303 study
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
AdvanTIG-205: phase 2 trial of ociperlimab (OCI) + tislelizumab (TIS) + chemotherapy (chemo) in first line (1L) treatment of patients (pts) with locally advanced (LA), unresectable, or metastatic non-small cell lung cancer (mNSCLC)
Final analysis of RATIONALE-301: randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Phase 3 study of tislelizumab (TIS) with sitravatinib versus chemotherapy (chemo) in patients with locally advanced/metastatic non-small cell lung cancer (NSCLC) previously treated with chemo and an anti-programmed cell death protein 1/ligand 1 (PD-[L]1) antibody
Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study
Septiembre 2022
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
PTHiT (Sociedad Polaca de Hematología y Medicina Transfusional)
Septiembre 2022 (Bydgoszcz, Polonia)
Presentaciones
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive CLL/SLL
Resúmenes
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab (BR) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Septiembre 2022
KSMO (Sociedad Coreana de Oncología Médica)
KSMO (Sociedad Coreana de Oncología Médica)
Septiembre 2022 (Seúl, Corea del Sur)
Presentaciones
HERIZON-GEA-01: a phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
HERIZON-GEA-01: phase 3 study of zanidatamab (ZANI) + chemotherapy (chemo) ± tislelizumab (TIS) in first-line (1L) human epidermal growth factor receptor 2 positive (HER2+) locally advanced (LA)/metastatic gastroesophageal adenocarcinoma (GEA)
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Agosto 2022
WCLC (World Congress on Lung Cancer)
WCLC (World Congress on Lung Cancer)
Agosto 2022 (Viena, Austria)
Pósteres
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, nonsquamous non-small cell lung cancer; SAFFRON-103
Safety and efficacy of sitravatinib plus tislelizumab in patients with PD-L1-positive, locally advanced or metastatic, squamous non-small cell lung cancer; SAFFRON-103
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer (NSCLC): final analysis of RATIONALE-303
Resúmenes
AdvanTIG-105: phase 1b dose-expansion study of ociperlimab plus tislelizumab in patients with metastatic NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, non-squamous NSCLC
Safety and efficacy of sitravatinib + tislelizumab in patients with PD-L1+, locally advanced/metastatic, squamous NSCLC
Tislelizumab versus docetaxel in previously treated advanced non-small cell lung cancer: final analysis of RATIONALE-303
Julio 2022
PPLC (Pan Pacific Lymphoma Conference)
PPLC (Pan Pacific Lymphoma Conference)
Julio 2022 (Kauai, Hawái)
Pósteres
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Zanubrutinib in 13 acalabrutinib‑intolerant patients with B‑Cell malignancies
Resúmenes
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
SEQUOIA: results of a phase 3 randomized study of zanubrutinib (ZANU) versus bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Zanubrutinib in 13 acalabrutinib‑intolerant patients (pts) with B‑cell malignancies
Junio 2022
WCGI (World Congress on Gastrointestinal Cancer)
WCGI (World Congress on Gastrointestinal Cancer)
Junio 2022 (Barcelona, España)
Pósteres
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma: RATIONALE-208 Chinese subpopulation
Resúmenes
RATIONALE-306: randomized, multi-regional, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC)
Subgroup analysis of the number of prior lines of systemic therapy and clinical outcomes associated with tislelizumab in patients with previously treated advanced hepatocellular carcinoma (HCC)
Tislelizumab monotherapy for patients with previously treated advanced hepatocellular carcinoma (HCC): RATIONALE-208 Chinese subpopulation
Junio 2022
AOS (Sociedad Asiática de Oncología)
AOS (Sociedad Asiática de Oncología)
Junio 2022 (Seúl, Corea)
Junio 2022
EHA (Asociación Europea de Hematología)
EHA (Asociación Europea de Hematología)
Junio 2022 (Viena, Austria)
Pósteres
A phase 1 first‑In‑human study of BGB‑16673, a Bruton tyrosine kinase protein degrader, in patients with B‑cell malignancies (trial in progress)
A phase 1 study with the novel BCL2 Inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: preliminary data
ASPEN: long‑term follow‑up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
View Summary of Poster in Plain Language
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib vs bendamustine plus rituximab (BR) in patients with treatment-naive (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
View Summary of Poster in Plain Language
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme data set
Preliminary safety and efficacy of BGB‑11417, a potent and selective B‑cell lymphoma 2 (BCL2) inhibitor, in patients with acute myeloid leukemia
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanubrutinib in older patients with relapsed/refractory marginal zone lymphoma (MZL): subgroup analysis of the Magnolia study
Resúmenes
A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress)
A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data
Efficacy of first-line treatment for chronic lymphocytic leukemia: a bayesian network meta-analysis
Health-related quality of life outcomes associated with zanubrutinib vs ibrutinib monotherapy in patients with relapsed/refractory (RR) CLL/SLL: results from the randomized phase 3 ALPINE trial
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Patient-reported outcomes from a phase 3 randomized study of zanubrutinib versus bendamustine plus rituximab (BR) in patients with treatment-naïve (TN) CLL/SLL
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Preliminary safety and efficacy of BGB-11417, a potent and selective B-cell lymphoma 2 (BCL2) inhibitor, in patients (pts) with acute myeloid leukemia (AML)
Real world evidence of impact of atrial fibrillation on clinical and economic outcomes in patients with chronic lymphocytic leukemia
Real-world treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors in patients with mantle cell lymphoma
Real-world treatment patterns and economic burden of patients with marginal zone lymphoma
Results of a phase 2 expanded access study of zanubrutinib in patients with Waldenström macroglobulinemia
Treatment persistence and adherence to ibrutinib in patients with Waldenstrӧm macroglobulinemia: a German claims data analysis
Zanubrutinib in acalabrutinib-intolerant patients (pts) with B-cell malignancies
Zanubrutinib in older patients (pts) with relapsed/refractory (R/R) marginal zone lymphoma (MZL): subgroup analysis of the MAGNOLIA study
Junio 2022
ASCO (Sociedad Estadounidense de Oncología Clínica)
ASCO (Sociedad Estadounidense de Oncología Clínica)
Junio de 2022 (Chicago, Illinois, EE. UU.)
Presentaciones
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
RATIONALE-309: updated PFS, PFS2, and OS from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer
Pósteres
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Tislelizumab, a PD‑1 inhibitor for relapsed/refractory mature (NK)/T‑cell neoplasms: results from a phase 2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanidatamab, a HER2-targeted bispecific antibody, in combination with tislelizumab and chemotherapy as first-line therapy for patients with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma: primary analysis of the phase 2 randomized ROSEWOOD trial
Resúmenes
A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM)
ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) vs ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
Efficacy of first-line treatment for chronic lymphocytic leukemia: a Bayesian network meta-analysis
Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia
Population-wide patterns of care in chronic lymphocytic leukemia in Australia: an analysis of the pharmaceutical benefits scheme dataset
Population-wide patterns of care in mantle cell lymphoma in Australia: an analysis of the pharmaceutical benefits scheme dataset
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (ESCC), RATIONALE 302: Asia subgroup
Real world evidence of impact of atrial fibrillation (AF) on clinical and economic outcomes in patients with chronic lymphocytic leukemia (CLL)
Real-world (RW) treatment patterns and comparative effectiveness of Bruton tyrosine kinase inhibitors (BTKi) in patients (pts) with mantle cell lymphoma (MCL)
Real-world treatment (tx) patterns and economic burden of patients (pts) with marginal zone lymphoma (MZL)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: results from a phase 2 study
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): preliminary results from a phase 1b/2 study
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: preliminary results from a phase 1b/2 study
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial
Mayo 2022
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
ISPOR (Sociedad Internacional de Farmacoeconomía e Investigación de Resultados)
Mayo 2022 (Washington, DC, Estados Unidos)
Mayo 2022
ICCEH (International Conference on Clinical and Experimental Hematology)
ICCEH (International Conference on Clinical and Experimental Hematology)
Mayo 2022 (Lublin, Polonia)
Abril 2022
TCT (Transplantation & Cellular Therapy)
TCT (Transplantation & Cellular Therapy)
Abril de 2022 (Salt Lake City, Utah, EE. UU.)
Abril 2022
Programa de la serie plenaria de ASCO (Sociedad Estadounidense de Oncología Clínica)
Programa de la serie plenaria de ASCO (Sociedad Estadounidense de Oncología Clínica)
Abril 2022 (virtual)
Presentaciones
Abril 2022
AACR (Asociación Estadounidense de Investigación en Cáncer)
AACR (Asociación Estadounidense de Investigación en Cáncer)
Abril de 2022 (Nueva Orleans, Luisiana, EE. UU.)
Pósteres
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
Co-enrichment of CD8 T-cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for non-squamous NSCLC in patients aged 65-75 years
RATIONALE-304: the association of tumor mutational burden with clinical outcomes of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer
The combination of hyperamplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab versus docetaxel in patients with previously treated advanced non-squamous (non-sq) non-small cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab versus docetaxel in patients with previously treated advanced squamous (sq) non-small cell lung cancer (NSCLC): subanalysis from phase 3 RATIONALE-303 randomized clinical study
Resúmenes
BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models
CD8 T cells and macrophage abundances associated with clinical benefit of tislelizumab in various tumor types
Pamiparib as a non-P-glycoprotein substrate PARP inhibitor can overcome ABCB1-mediated multidrug resistance in ovarian cancer cells
Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies
RATIONALE 304: tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65–75 years
RATIONALE-304: the association of tumor mutational burden (TMB) with clinical outcomes of tislelizumab (TIS) + chemotherapy (chemo) versus chemo alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced non-squamous (non-sq) non-small-cell lung cancer (NSCLC): subanalysis from the RATIONALE-303 phase 3 randomized clinical study
Tislelizumab (TIS) versus docetaxel (D) in patients with previously treated advanced squamous (sq) non-small-cell lung cancer (NSCLC): sub-analysis from phase 3 RATIONALE-303 randomized clinical study
Abril 2022
BSH (Sociedad Británica de Hematología)
BSH (Sociedad Británica de Hematología)
Abril 2022 (Manchester, Reino Unido)
Pósteres
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Resúmenes
First interim analysis of ALPINE study: results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
SEQUOIA: results of a phase 3 randomized study of zanubrutinib versus bendamustine + rituximab in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
Marzo 2022
SIES (Sociedad Italiana de Hematología Experimental)
SIES (Sociedad Italiana de Hematología Experimental)
Marzo 2022 (Roma, Italia)
Marzo 2022
KSH (Sociedad Coreana de Hematología)
KSH (Sociedad Coreana de Hematología)
Marzo 2022 (Seúl, Corea del Sur)
Marzo 2022
ELCC (Congreso Europeo de Cáncer de Pulmón)
ELCC (Congreso Europeo de Cáncer de Pulmón)
Marzo 2022 (virtual)
Pósteres
AdvanTIG-204: anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab plus concurrent chemoradiotherapy in patients with untreated limited-stage small cell lung cancer
RATIONALE-307: safety analysis of patients receiving tislelizumab plus chemotherapy versus chemotherapy alone in advanced squamous NSCLC
Resúmenes
AdvanTIG-204: anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
RATIONALE-307: safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC
Marzo 2022
SFH (Sociedad Francesa de Hematología)
SFH (Sociedad Francesa de Hematología)
Marzo 2022 (París, Francia)
Marzo 2022
SGO (Sociedad de Oncología Ginecológica)
SGO (Sociedad de Oncología Ginecológica)
Marzo 2022 (Phoenix, Arizona, Estados Unidos)
Pósteres
AdvanTIG-202: a phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously-treated, locally advanced unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
Resúmenes
AdvanTIG-202: a phase 2 study investigating anti-T cell immunoglobulin and ITIM domain monoclonal antibody ociperlimab plus tislelizumab in patients with previously treated recurrent or metastatic cervical cancer
Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: gynecological cancer subgroup
Marzo 2022
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
JFHOD (Días francófonos de hepatogastroenterología y oncología digestiva)
Marzo 2022 (París, Francia)
Marzo 2022
ESMO TAT (Terapias oncológicas dirigidas de la Sociedad Europea de Oncología Médica)
ESMO TAT (Terapias oncológicas dirigidas de la Sociedad Europea de Oncología Médica)
Marzo 2022 (virtual)
Pósteres
Febrero 2022
JSMO (Sociedad Japonesa de Oncología Médica)
JSMO (Sociedad Japonesa de Oncología Médica)
Febrero 2022 (Kioto, Japón)
Enero 2022
BTOG (Grupo Británico de Oncología Torácica)
BTOG (Grupo Británico de Oncología Torácica)
Enero 2022 (virtual)
Enero 2022
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
ASCO-GI (Sociedad Estadounidense de Oncología Clínica - Simposio de Cánceres Gastrointestinales)
Enero de 2022 (San Francisco, California, EE. UU.)
Pósteres
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT monoclonal antibody ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody ociperlimab + anti-PD-1 monoclonal antibody tislelizumab + BAT1706 vs tislelizumab + BAT1706 as first-line treatment for unresectable hepatocellular carcinoma
Clinical outcomes associated with tislelizumab in patients with advanced hepatocellular carcinoma who have been previously treated with sorafenib or lenvatinib in RATIONALE-208
Clinical outcomes in patients with previously treated advanced hepatocellular carcinoma experiencing hepatitis B virus DNA increases during tislelizumab treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with unresectable locally advanced or metastatic hepatocellular carcinoma
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life
Updated analysis from a phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors
Resúmenes
AdvanTIG-203: a randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab vs tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1)
AdvanTIG-206: anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 vs TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC)
Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208
Clinical outcomes in patients (pts) with previously treated advanced hepatocellular carcinoma (HCC) experiencing hepatitis B virus (HBV) DNA increases during tislelizumab (TIS) treatment in RATIONALE-208
DKN-01 and tislelizumab ± chemotherapy as first-line (1L) or second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)
Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC)
Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): impact on health-related quality of life (HRQoL)
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
Diciembre 2021
ASH (Sociedad Estadounidense de Hematología)
ASH (Sociedad Estadounidense de Hematología)
Diciembre 2021 (Atlanta, Georgia, Estados Unidos)